Prediction: This Stock Could Double Over the Next 5 Years

Viking Therapeutics' weight loss drug VK2735 shows strong clinical promise with potential for dual-formulation therapy (injectable followed by oral maintenance). The company raised $500 million to fund pipeline development. With the obesity drug market projected to reach $77 billion by 2030, even a small 1.4% market share could generate $1.2 billion in revenue for Viking's $4 billion market cap, suggesting significant upside potential, though clinical trial risks remain.

10/02/2026, 6:15 AM • The Motley Fool

Eli Lilly Stock Barely Moved Following Viking Therapeutics' Impressive Clinical Results. Here's Why.

Viking Therapeutics released impressive clinical trial results for its weight-loss drug VK2735, showing 16-19% body weight loss and strong maintenance results. However, Eli Lilly's stock barely moved because the company has its own robust maintenance strategies (Foundayo and dose reduction approaches) and a deeper pipeline. While Viking could become a competitor in the growing weight-loss market, it still needs to confirm results in larger Phase 3 trials, and Eli Lilly remains the safer, more established choice.

09/29/2026, 5:30 PM • The Motley Fool

Could This Mid-Cap GLP-1 Stock Be a Better Buy Than Eli Lilly?

Viking Therapeutics' GLP-1 drug VK2735 showed promising clinical trial results with 16-19% weight loss and strong maintenance rates, causing the stock to surge. While riskier than Eli Lilly due to its smaller $4.1B market cap and lack of approved drugs, Viking could offer significant upside potential through drug approval or acquisition by a larger healthcare company.

09/28/2026, 9:01 AM • The Motley Fool

Viking Therapeutics Soared After Its Latest GLP-1 Data. Is It Too Late to Buy?

Viking Therapeutics released positive maintenance dosing data for its GLP-1 drug candidate VK2735, causing the stock to surge 35%. The company is positioning itself as a potential competitor in the $100 billion weight loss drug market dominated by Eli Lilly and Novo Nordisk. Viking's dual GLP-1/GIP agonist could be the first oral formulation of its kind, with both injectable and oral versions available, offering advantages over current competitors.

09/25/2026, 6:05 AM • The Motley Fool

Here's Why Viking Therapeutics Shares Slumped Today

Viking Therapeutics stock declined 14.5% following the announcement of a capital raise ($275 million in common stock and $225 million in convertible notes), not due to negative trial results. The company's maintenance study for its weight-loss drug VK2735 showed positive results, prompting management to upsize the offering from initial plans. The stock correction reflects profit-taking after trading above $41 prior to the $35 offering price announcement.

09/24/2026, 11:30 AM • The Motley Fool

Why Viking Therapeutics Stock Skyrocketed on Tuesday

Viking Therapeutics' stock surged 35.67% after announcing positive clinical trial results for its obesity drug VK2735. Participants lost 16-19% of body weight over 21 weeks and maintained up to 97% of weight loss with flexible dosing schedules. The drug showed strong tolerability with low discontinuation rates, positioning Viking as a potential challenger in the rapidly expanding obesity drug market projected to reach $150 billion by 2035.

09/23/2026, 12:04 AM • The Motley Fool

3 Wall Street Analysts Think Viking Therapeutics Stock Will Roughly Triple Over the Next 12 Months. Here's Why I Think They're Wrong

While three Wall Street analysts have bullish $100 price targets on Viking Therapeutics (implying a tripling), the author argues this is overly optimistic. Viking's weight-loss drug VK2735 would need near-flawless phase 3 data showing 23-26% mean weight loss to justify such gains, and any clinical setback could sink the stock. The author recommends only risk-tolerant investors consider a small position.

09/03/2026, 4:30 PM • The Motley Fool

Viking Therapeutics Has $502 Million in Cash and 1 Big Catalyst Left in 2026 -- Is That Enough?

Viking Therapeutics has sufficient cash reserves ($502M) to fund operations through 2028, with a key near-term catalyst in Q3 2026 when phase 1 maintenance trial data for its lead drug VK2735 will be released. This data could significantly impact investor sentiment regarding the company's dual-formulation strategy (subcutaneous injection followed by oral maintenance), though it's unlikely to derail the ongoing phase 3 trials. The trial results will inform dosing decisions for upcoming extension studies.

08/27/2026, 10:45 AM • The Motley Fool

Better GLP-1 Stock to Buy: Eli Lilly or Viking Therapeutics?

Eli Lilly and Viking Therapeutics are competing in the rapidly growing GLP-1 drug market. Eli Lilly leads with approved products like tirzepatide generating strong revenue ($9.9B for Mounjaro, $4.9B for Zepbound in Q2), while Viking Therapeutics is a clinical-stage biotech with promising VK2735 candidate showing strong phase 2 results. The article recommends Eli Lilly as the safer choice due to its established portfolio and limited downside risk, though Viking Therapeutics offers higher upside potential if its phase 3 trials succeed.

08/08/2026, 3:30 PM • The Motley Fool

Viking Therapeutics Declined in July, and why its Long-Term Prospects are Undiminished

Viking Therapeutics stock fell 18.6% in July as investors focused on the company's cash burn ($96M quarterly) and potential shareholder dilution from a planned $500M equity offering, despite positive progress on its phase 3 trials for weight-loss drug VK2735. The company has sufficient cash through 2028 and expects trial results by then, maintaining long-term potential in the weight-loss drug market.

08/06/2026, 10:21 AM • The Motley Fool

Vertex Just Paid $10 Billion for Crinetics. Here's Why Viking Therapeutics Could Be the Next Big Pharma Takeover Target

Following Vertex Pharmaceuticals' $10 billion acquisition of Crinetics, Viking Therapeutics emerges as a potential takeover target due to its promising weight-loss drug pipeline, particularly VK2735 in phase 3 trials. The anti-obesity market is projected to reach $190 billion by 2035, making it attractive for pharmaceutical giants seeking to acquire proven candidates rather than develop from scratch. However, Viking's stock carries significant risk tied to upcoming phase 3 data readouts.

07/30/2026, 6:30 PM • The Motley Fool

Should You Buy Viking Therapeutics Stock on the Dip? Wall Street Is Screaming "Yes."

Wall Street analysts are bullish on Viking Therapeutics (VKTX), with a consensus price target of $91 representing a potential 150% return. The optimism centers on VK2735, a dual-formulation weight-loss drug showing promising phase 2 efficacy data. However, key phase 3 results won't arrive until late 2027-2028, and some phase 2 oral trial tolerability concerns exist. Cautious investors may want to wait for upcoming maintenance trial results before investing.

07/18/2026, 9:30 AM • The Motley Fool

Kuehn Law Encourages Investors of Viking Therapeutics, Inc. to Contact Law Firm

Kuehn Law is investigating whether officers and directors of Viking Therapeutics breached fiduciary duties to shareholders through potential self-dealing. The firm is seeking long-term VKTX stockholders to participate in shareholder litigation, offering free consultations with no obligation.

07/16/2026, 9:31 PM • GlobeNewswire

Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law Firm

Kuehn Law is investigating whether officers and directors of Rhythm Pharmaceuticals breached fiduciary duties to shareholders through potential self-dealing. Long-term shareholders may be entitled to damages and corporate governance reforms. The law firm is also investigating similar matters at Travere Therapeutics and Viking Therapeutics.

07/16/2026, 9:16 PM • GlobeNewswire

Is It Too Late to Buy Eli Lilly?

Eli Lilly stock has surged 400% over five years, driven by dominance in the GLP-1 weight loss drug market with products like Mounjaro and Zepbound generating over $12 billion in recent quarterly sales. Despite the stock's significant gains and current $1,200+ price, analysts suggest it remains reasonably valued with strong growth prospects from its oral drug Foundayo and promising pipeline candidate retatrutide, making it still worth considering for investors.

07/08/2026, 2:10 PM • The Motley Fool